1. Home
  2. LOB vs AGIO Comparison

LOB vs AGIO Comparison

Compare LOB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOB
  • AGIO
  • Stock Information
  • Founded
  • LOB 2008
  • AGIO 2007
  • Country
  • LOB United States
  • AGIO United States
  • Employees
  • LOB N/A
  • AGIO N/A
  • Industry
  • LOB Major Banks
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOB Finance
  • AGIO Health Care
  • Exchange
  • LOB Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • LOB 1.3B
  • AGIO 1.4B
  • IPO Year
  • LOB 2015
  • AGIO 2013
  • Fundamental
  • Price
  • LOB $32.27
  • AGIO $36.07
  • Analyst Decision
  • LOB Buy
  • AGIO Buy
  • Analyst Count
  • LOB 3
  • AGIO 6
  • Target Price
  • LOB $41.33
  • AGIO $58.60
  • AVG Volume (30 Days)
  • LOB 240.4K
  • AGIO 524.8K
  • Earning Date
  • LOB 07-23-2025
  • AGIO 07-31-2025
  • Dividend Yield
  • LOB 0.37%
  • AGIO N/A
  • EPS Growth
  • LOB N/A
  • AGIO N/A
  • EPS
  • LOB 1.30
  • AGIO 11.45
  • Revenue
  • LOB $399,322,000.00
  • AGIO $37,035,000.00
  • Revenue This Year
  • LOB $41.81
  • AGIO $22.30
  • Revenue Next Year
  • LOB $10.77
  • AGIO $219.19
  • P/E Ratio
  • LOB $24.80
  • AGIO $3.15
  • Revenue Growth
  • LOB N/A
  • AGIO 25.96
  • 52 Week Low
  • LOB $22.68
  • AGIO $23.42
  • 52 Week High
  • LOB $50.57
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • LOB 73.82
  • AGIO 62.76
  • Support Level
  • LOB $29.60
  • AGIO $32.87
  • Resistance Level
  • LOB $29.99
  • AGIO $35.85
  • Average True Range (ATR)
  • LOB 0.80
  • AGIO 1.38
  • MACD
  • LOB 0.33
  • AGIO -0.05
  • Stochastic Oscillator
  • LOB 94.89
  • AGIO 76.58

About LOB Live Oak Bancshares Inc.

Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: